PMID- 37278044
OWN - NLM
STAT- MEDLINE
DCOM- 20230823
LR  - 20230823
IS  - 2212-3989 (Electronic)
IS  - 1871-5265 (Linking)
VI  - 23
IP  - 6
DP  - 2023
TI  - Naloxone Effects Against Cutaneous Leishmaniasis Caused by Leishmania major 
      Strain MRHO/IR/75/ER in the BALB/c Mice.
PG  - e020623217598
LID - 10.2174/1871526523666230602113613 [doi]
AB  - INTRODUCTION: Cutaneous leishmaniasis (CL) is a serious health problem in some 
      parts of the world, such as Iran. Since the use of pentavalent antimonial 
      compounds such as meglumine antimoniate (Glucantime, MA) for the treatment of CL 
      has side effects, naloxone as a new treatment in the footpad of Leishmania major 
      (L. major)-infected BALB/c mice was investigated by evaluating the lesion size 
      and the parasite burden. METHOD: The animals were infected with L. major 
      (MRHO/IR/75/ER). 40 BALB/c mice were divided into 4 groups (10/group), and were 
      treated as follows 39 days after L. major infection: Group 1 treated with 
      intraperitoneal injections of MA (100 mg/kg, positive control group) daily for 
      six weeks; Group 2 received a 100 mul injection of PBS (negative control group); 
      Group 3 received subcutaneous (SC) injections of naloxone (10 mg/kg) daily for 
      six weeks (Naloxone1), and Group 4 was SC injected with naloxone (10 mg/kg) 
      weekly for six weeks (Naloxone2). The lesion size was measured using a digital 
      caliper. RESULT: After the end of treatment, the lesion parasite burden was 
      evaluated. As compared to the negative control group, the groups that received MA 
      and naloxone (groups 1, 3, and 4) showed fewer parasites. Also, the 
      naloxone-treated mice showed significantly smaller lesion sizes than the negative 
      control group (p<0.05), but they did not differ significantly from the MA-treated 
      mice. CONCLUSION: Taken together, the results suggest that naloxone might be a 
      promising and alternative treatment for CL.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Azizi, Hakim
AU  - Azizi H
AUID- ORCID: 0000-0003-4804-6991
AD  - Department of Parasitology and Mycology, School of Medicine Zabol University of 
      Medical Sciences, Zabol, Iran.
AD  - Zabol Medicinal Plants Research Center, Zabol University of Medical Sciences, 
      Zabol, Iran.
FAU - Mahdavinik, Elham
AU  - Mahdavinik E
AD  - Department of Parasitology and Mycology, School of Medicine Zabol University of 
      Medical Sciences, Zabol, Iran.
FAU - Hataminejad, Maryam
AU  - Hataminejad M
AUID- ORCID: 0000-0002-9094-5424
AD  - Department of Medical Parasitology, School of Medicine, Mazandaran University of 
      Medical Sciences, Sari, Iran.
AD  - Toxoplasmosis Research Center, Mazandaran University of Medical Sciences, Sari, 
      Iran.
AD  - Student Research Committee, Mazandaran University of Medical Sciences, Sari, 
      Iran.
FAU - Khamesipour, Ali
AU  - Khamesipour A
AD  - Center for Research and Training in Skin Diseases and Leprosy, Tehran University 
      of Medical Sciences, Tehran, Iran.
FAU - Montazeri, Sareh
AU  - Montazeri S
AD  - Department of Parasitology and Mycology, School of Medicine Zabol University of 
      Medical Sciences, Zabol, Iran.
LA  - eng
GR  - IR.ZBMU.REC.1397.200/Zabol University of Medical Sciences/
PT  - Journal Article
PL  - United Arab Emirates
TA  - Infect Disord Drug Targets
JT  - Infectious disorders drug targets
JID - 101269158
RN  - 75G4TW236W (Meglumine Antimoniate)
RN  - 0 (Antiprotozoal Agents)
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Leishmania major
MH  - Mice, Inbred BALB C
MH  - *Leishmaniasis, Cutaneous/drug therapy
MH  - Meglumine Antimoniate/therapeutic use
MH  - Skin
MH  - *Antiprotozoal Agents/pharmacology/therapeutic use
OTO - NOTNLM
OT  - BALB/C mice
OT  - Leishmania major
OT  - Naloxone
OT  - cutaneous leishmaniasis
OT  - glucantime
OT  - treatment
EDAT- 2023/06/06 06:42
MHDA- 2023/08/23 06:42
CRDT- 2023/06/06 03:40
PHST- 2023/01/07 00:00 [received]
PHST- 2023/03/24 00:00 [revised]
PHST- 2023/05/08 00:00 [accepted]
PHST- 2023/08/23 06:42 [medline]
PHST- 2023/06/06 06:42 [pubmed]
PHST- 2023/06/06 03:40 [entrez]
AID - IDDT-EPUB-132248 [pii]
AID - 10.2174/1871526523666230602113613 [doi]
PST - ppublish
SO  - Infect Disord Drug Targets. 2023;23(6):e020623217598. doi: 
      10.2174/1871526523666230602113613.